ARWR241115P18000
- 0.25
- 0.000.00%
Arrowhead Pharmaceuticals Newsroom
Arrowhead Pharma Analyst Ratings
H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $60
Buy Rating Justified by Arrowhead Pharmaceuticals' Advancements in CNS-Targeted RNAi Therapeutics
A Quick Look at Today's Ratings for Arrowhead Pharmaceuticals(ARWR.US), With a Forecast Between $28 to $62
TD Cowen Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating
Piper Sandler Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $62
Morgan Stanley Maintains Arrowhead Pharmaceuticals(ARWR.US) With Hold Rating, Maintains Target Price $29
Maintaining Hold on Arrowhead Pharmaceuticals Amid Promising CNS Portfolio Developments
Arrowhead Pharma Analyst Ratings
RBC Capital Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Cuts Target Price to $42
Arrowhead Pharmaceuticals (ARWR) Receives a Buy From RBC Capital
H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $60
TD Cowen Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating
A Quick Look at Today's Ratings for Arrowhead Pharmaceuticals(ARWR.US), With a Forecast Between $27 to $60
Hold Rating on Arrowhead Pharmaceuticals Amid Promising Clinical Data and Upcoming Regulatory Hurdles
Arrowhead Pharma Analyst Ratings
B.Riley Financial Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $55
Chardan Capital Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $60
TD Cowen Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating
TD Cowen Reaffirms Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)